3,5-二碘代水杨酸钾 | 17274-17-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二碘代水杨酸钾
• 中文别名: 3,5-二碘水杨酸钾
• 英文名称: Sodium 2-carboxy-4,6-diiodophenolate
• 英文别名: sodium;2-carboxy-4,6-diiodophenolate
• CAS: 17274-17-8
• 化学式: C7H3I2NaO3
• 分子量: 411.9
• InChiKey: PBMNRTLTNHTZRR-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -2.03
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2918290000

反应信息

• 作为反应物：
  描述：

  3,5-二碘代水杨酸钾 、 硫酸,铜(2+)盐,碱性的 生成 Bis(3,5-diiodosalicylato)copper
  参考文献：
  名称：

  MELNIK, MILAN;MROZINSKI, JERZY, MATER. SCI., 14,(1988) N, C. 61-65

  摘要：

  DOI：

文献信息

• An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant
  申请人：INTERx RESEARCH CORPORATION

  公开号：EP0036534A1

  公开（公告）日：1981-09-30

  A drug form is provided for increasing the oral absorption of β-lactam antibiotics such as the penicillins, cephalosporins and related chemical species by the oral administration of said β-lactam antibiotics in a suitable pharmaceutically accepted excipient to which has been added a hydroxy aryl or hydroxy aralkyl acid or salt, amide or ester thereof. The hydroxyaryl or hydroxyaralkyl acid or salt, amide or ester thereof is present in the drug form in quantities sufficient to be effective in enhancing the rate of oral absorption of the β-lactam antibiotic.

  本发明提供了一种药物形式，通过将β-内酰胺类抗生素口服于适当的药学上可接受的赋形剂中，并在赋形剂中加入羟基芳基或羟基芳烷基酸或其盐、酰胺或酯，从而增加β-内酰胺类抗生素如青霉素类、头孢菌素类及相关化学物质的口服吸收。羟基芳基或羟基烷基酸或其盐、酰胺或酯在药物形式中的含量足以有效提高 β-内酰胺类抗生素的口服吸收率。
• PHOTOSENSITIVE COMPOSITION AND USE THEREOF
  申请人：SANYO CHEMICAL INDUSTRIES, LTD.

  公开号：EP0930540A1

  公开（公告）日：1999-07-21

  The present invention is related to a photosensitive composition which comprises 70 to 99 weight % of a vinyl polymer (A) comprising recurring units derived from a monomer (a) of the following general formula (1) and 1 to 30 weight % of at least one photosensitive compound (B) selected from the group consisting of azide compounds and diazo compounds.         H2C=CH-X-Q     (1) [wherein X is selected from the group consisting of a direct bond, a 1,4-phenylene group, a sulfonyl group, a methylene group, and an alkylene group of 2 to 5 carbon atoms (the methylene and alkylene groups may respectively have one ether, carbonyl, carboxyl, amide or urea group); Q represents a functional group selected from the group consisting of -NH-R, -COCH2COCH3, and -SO2NH2; R represents a residue selected from the group consisting of -CHO, -H (hydrogen), an alkyl group of 1 to 6 carbon atoms (the alkyl group may have one hydroxyl, ether, amino, nitro, cyano, carbonyl, carboxyl, amide, or urea group), -NH2, -N(CH3)2, -COOH, -CONH2 and -CONHCH3]

  本发明涉及一种光敏组合物，它包括 70 至 99 重量百分比的乙烯基聚合物 (A)，该聚合物包含从下通式 (1) 单体 (a) 衍生的递归单元，以及 1 至 30 重量百分比的至少一种光敏化合物 (B)，该化合物选自叠氮化合物和重氮化合物组成的组。 H2C=CH-X-Q (1) [其中 X 选自直接键、1,4-亚苯基、磺酰基、亚甲基和 2 至 5 个碳原子的亚烷基（亚甲基和亚烷基可分别具有一个醚基、羰基、羧基、酰胺基或脲基）组成的组；Q 代表从 -NH-R、-COCH2CO 和 -SO2NH2 所组成的组中选出的官能团；R 代表从 -CHO、-H（氢）、1 至 6 个碳原子的烷基（烷基可分别具有一个羟基、醚基、氨基、硝基、氰基、羰基、羧基、酰胺基或脲基）、-NH2、-N(CH3)2、-COOH、-CONH2 和 -CONH 所组成的组中选出的残基。］
• Delivery of drug nanoparticles and methods of use thereof
  申请人：DFB Soria, LLC

  公开号：US10449162B2

  公开（公告）日：2019-10-22

  Disclosed are compositions and methods useful for enhancing the skin penetration of drug nanoparticles. The compositions can be hydrophobic and include a hydrophobic carrier, a volatile silicone fluid, and drug nanoparticles. Also disclosed are methods for inhibiting crystal growth of drug nanoparticles in an aqueous carrier or a hydrophobic carrier. Further, methods to topically treat psoriasis using compositions containing nanoparticles of paclitaxel or other taxanes are disclosed.

  所公开的是用于增强药物纳米粒子皮肤渗透性的组合物和方法。这些组合物可以是疏水性的，包括疏水载体、挥发性硅油和药物纳米粒子。还公开了在水性载体或疏水性载体中抑制药物纳米粒子晶体生长的方法。此外，还公开了使用含有紫杉醇或其他类固醇的纳米颗粒的组合物局部治疗牛皮癣的方法。
• Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
  申请人：DFB SORIA, LLC

  公开号：US10555898B2

  公开（公告）日：2020-02-11

  Disclosed are methods useful for the topical therapeutic treatment of skin malignancies including skin cancers and cutaneous metastases using compositions containing nanoparticles of paclitaxel or other taxanes.

  公开了使用含有紫杉醇或其他类固醇纳米颗粒的组合物局部治疗皮肤恶性肿瘤（包括皮肤癌和皮肤转移瘤）的方法。
• Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
  申请人：CRITITECH, INC.

  公开号：US11058639B2

  公开（公告）日：2021-07-13

  Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, and intracystic injection.

  所公开的是通过将局部给药含有抗肿瘤微粒（如紫杉烷微粒）的组合物与全身给药含有免疫治疗剂的组合物相结合来治疗癌症的组合治疗方法。局部给药方法包括局部应用、肺部给药、瘤内注射、腹膜内注射和囊内注射。